Ultragenyx Pharmaceutical Inc. (RARE)

Nasdaq: RARE · Pharmaceutical Preparations · Novato, CA · filing with the SEC since 2011

Full chart Alerts Compare

Grade5.9

◀ Past 7.5● Present 5.9▶ Future 4.5

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$673M+20.2%

Net income-$575M-1.1%

Earnings per share$-5.83+7.3%

Operating cash flow-$466M-12.6%

Cash$421M+142.0%

Debtn/a

Shareholders’ equity-$80.0M-131.4%

Shares, diluted98.6M+9.0%

Return on equityn/a

The recordfrom its filings

Filings in 202694

Newest filingNov 10 · SCHEDULE 13G

Annual reportFeb 18, 2026

Quarterly reportNov 4, 2026

Next report due10-K by Mar 1

Insider sales, 12 months$3.8M

Insider buys, 12 months$0.00

Patents granted28

Filer categoryLarge accelerated filer

Trailing twelve months to Sep 2026Revenue $730MNet income -$524MCash from operations -$437Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Nov 4, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 3, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Oct 30, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Oct 20, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Oct 19, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Oct 19, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 14, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 7, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Sep 17, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Ultragenyx Pharmaceutical Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Novato, CA. Product was 55% of fiscal 2025 revenue.

Newest on the record

Large holder notice on Nov 10. Before it, quarterly report on Nov 4.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 1, 2027.

About RARE

Ultragenyx Pharmaceutical Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Novato, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $673 million and a loss of $575 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersNovato, CA

Business modelProduct business

ExchangeNasdaq

Filing since2011

Fiscal year endsDec 31

SEC number (CIK)1515673

Peers on fileLGND, PAHC, ACAD, SUPN

Who runs it

Financial performance

In fiscal 2025 Ultragenyx Pharmaceutical’s revenue was $673.0 million, up 20.2% from $560.0 million the year before. It made a net loss of $575.0 million.

Annual report, filed Feb 18, 2026.

Financial statements

The grade

Ultragenyx Pharmaceutical grades 5.9 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Eight of the nine metrics are read as filed and one is an SI estimate, each with its reasoning.

◀ Past7.5

● Present5.9

▶ Future4.5

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton RARE · research, not advice